Harbin Pharmaceutical Group Co

Harbin Pharmaceutical Group Co OCF/Debt

The Operating Cash Flow to Debt Ratio of Harbin Pharmaceutical Group Co (600664.SS) as of Nov 16, 2026 is 1,396.68 %. In the previous year, Operating Cash Flow to Debt Ratio was 48.87 % — a change of 2,757.69% (higher).

OCF/Debt

1,396.68 %

YoY

2,757.69%

Last updated:

Operating Cash Flow to Debt Ratio of Harbin Pharmaceutical Group Co is 2025 1,396.68 % . Operating Cash Flow to Debt Ratio of Harbin Pharmaceutical Group Co was 2024 48.87 % . It decreases by 2,757.69% higher compared to the previous year.

The Harbin Pharmaceutical Group Co OCF/Debt history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

OCF/Debt
Date
OCF/Debt
Jan 1, 2018
272.53 CNY
Jan 1, 2019
-42.33 CNY
Jan 1, 2020
-41.05 CNY
Jan 1, 2021
-7.02 CNY
Jan 1, 2022
28.84 CNY
Jan 1, 2023
55.16 CNY
Jan 1, 2024
48.87 CNY
Jan 1, 2025
1,396.68 CNY
The Harbin Pharmaceutical Group Co OCF/Debt history
YEAROCF/DebtYoY
1,396.68 %+2,757.69%
48.87 %-11.39%
55.16 %+91.25%
28.84 %-510.67%
-7.02 %-82.89%
-41.05 %-3.03%
-42.33 %-115.53%
272.53 %+378.86%
56.91 %-96.96%
1,873.32 %+123.05%
839.86 %+21.77%
689.69 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Harbin Pharmaceutical Group Co Stock analysis

What does Harbin Pharmaceutical Group Co do? Harbin Pharmaceutical Group Co., Ltd. generates revenue by engaging in the research, development, manufacture, wholesale, and retail of pharmaceutical products. The firm focuses on innovative research and development in high-tech fields such as antibiotics, modern Chinese medicine, and biopharmaceuticals. These activities support its main business sectors, which include antibiotics, over-the-counter drugs and health products, traditional and modern Chinese medicine, biomedicine, and pharmaceutical commerce. The company produces a wide range of items, including calcium gluconate oral solution, zinc gluconate oral solution, amoxicillin capsules, Shuanghuanglian oral solution, alprostadil injection, pediatric paracetamol Huangnamin granules, lacidipine tablets, hydrochloric acid for injection Cefotiam, ibuprofen granules, and Xingaizhonggai high calcium tablets. The business is structured around these diverse product lines, serving the needs of the pharmaceutical commerce sector and consumers requiring specific medical treatments. By covering the entire value chain from research and development to retail, the company monetizes its expertise in high-tech fields. The products listed, such as Shuanghuanglian oral solution and amoxicillin capsules, represent the tangible outputs of its manufacturing and wholesale operations, which are central to its financial model. Harbin Pharmaceutical Group Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Harbin Pharmaceutical Group Co stock

Operating Cash Flow to Debt Ratio of Harbin Pharmaceutical Group Co is 1,396.68 % in 2025.

Operating Cash Flow to Debt Ratio of Harbin Pharmaceutical Group Co changed from 48.87 % to 1,396.68 %, representing a 2,757.69% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Operating Cash Flow to Debt Ratio Harbin Pharmaceutical Group Co since 2006 – with annual values, charts, and detailed analysis.

OCF/Debt measures what percentage of total debt can be covered by annual operating cash flow. Higher ratios indicate stronger debt repayment capacity.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Operating Cash Flow to Debt Ratio's Harbin Pharmaceutical Group Co with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Leverage — Harbin Pharmaceutical Group Co

All Key Metrics — Harbin Pharmaceutical Group Co